TransCode Therapeutics (NASDAQ:RNAZ) Price Target Raised to $20.00

TransCode Therapeutics (NASDAQ:RNAZ) had its target price upped by HC Wainwright from $3.00 to $20.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for TransCode Therapeutics’ Q1 2025 earnings at ($1.48) EPS, Q2 2025 earnings at ($1.64) EPS, Q3 2025 earnings at ($1.02) EPS and Q4 2025 earnings at ($0.78) EPS.

TransCode Therapeutics Price Performance

Shares of NASDAQ:RNAZ opened at $3.76 on Wednesday. TransCode Therapeutics has a 12-month low of $3.21 and a 12-month high of $264.00. The firm has a fifty day moving average of $380.38 and a two-hundred day moving average of $553.50.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management lifted its position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,138 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned about 0.29% of TransCode Therapeutics worth $29,000 as of its most recent filing with the SEC.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.